Lisa M Mccarthy Pharm D

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1958204/publications.pdf

Version: 2024-02-01

55 papers

1,195 citations

20 h-index 32 g-index

59 all docs

59 docs citations

59 times ranked

1410 citing authors

#	Article	lF	CITATIONS
1	Tool development to improve medication information transfer to patients during transitions of care: A participatory action research and design thinking methodology approach. Research in Social and Administrative Pharmacy, 2022, 18, 2170-2177.	3.0	12
2	Exploring medication self-management in community-dwelling adults with chronic medication experience: A concept mapping study. Research in Social and Administrative Pharmacy, 2022, 18, 2854-2866.	3.0	3
3	Benefits and Harms of Deprescribing Antihyperglycemics for Adults With Type 2 Diabetes: A Systematic Review. Canadian Journal of Diabetes, 2022, 46, 473-479.	0.8	5
4	"Talking About Your Medications― A workshop series aimed at helping older adults participate in conversations about their medications. Canadian Pharmacists Journal, 2022, 155, 86-92.	0.8	6
5	Medication Supports at Transitions Between Hospital and Other Care Settings: A Rapid Scoping Review. Patient Preference and Adherence, 2022, Volume 16, 515-560.	1.8	O
6	Helping Unlock Better Care (HUB C) using quality improvement science in community pharmacies – An implementation method. Research in Social and Administrative Pharmacy, 2021, 17, 572-577.	3.0	7
7	Identifying key prescribing cascades in older people (iKASCADE): a transnational initiative on drug safety through a sex and gender lens—rationale and design. European Geriatric Medicine, 2021, 12, 475-483.	2.8	7
8	Evidence of a gabapentinoid and diuretic prescribing cascade among older adults with lower back pain. Journal of the American Geriatrics Society, 2021, 69, 2842-2850.	2.6	16
9	Medication Management Frameworks in the Context of Self-Management: A Scoping Review. Patient Preference and Adherence, 2021, Volume 15, 1311-1329.	1.8	3
10	Perspectives on ageing: a qualitative study of the expectations, priorities, needs and values of older people from two Canadian provinces. Age and Ageing, 2021, 50, 1811-1819.	1.6	6
11	Clinical learnings from a virtual primary care program monitoring mild to moderate COVID-19 patients at home. Family Practice, 2021, 38, 549-555.	1.9	16
12	Best Possible Medication Histories by Registered Pharmacy Technicians in Ambulatory Care. Canadian Journal of Hospital Pharmacy, 2021, 74, 149-155.	0.1	O
13	Pharmacists as Personalized Medicine Experts (PRIME): Experiences Implementing Pharmacist-Led Pharmacogenomic Testing in Primary Care Practices. Pharmacy (Basel, Switzerland), 2021, 9, 201.	1.6	8
14	Community pharmacists as catalysts for deprescribing: An exploratory study using quality improvement processes. Canadian Pharmacists Journal, 2020, 153, 37-45.	0.8	17
15	Quality improvement: A strategy to accelerate pharmacist integration into team-based primary care practice. Canadian Pharmacists Journal, 2020, 153, 274-279.	0.8	5
16	Community pharmacists' evolving role in Canadian primary health care: a vision of harmonization in a patchwork system. Pharmacy Practice, 2020, 18, 2171.	1.5	29
17	Patient and provider perspectives on the development and resolution of prescribing cascades: a qualitative study. BMC Geriatrics, 2020, 20, 368.	2.7	15
18	Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension. JAMA Internal Medicine, 2020, 180, 643.	5.1	63

#	Article	IF	CITATIONS
19	A developmental evaluation of an intraprofessional Pharmacy Communication Partnership (PROMPT) to improve transitions in care from hospital to community: A mixed-methods study. BMC Health Services Research, 2020, 20, 99.	2.2	9
20	Exploring deprescribing opportunities for community pharmacists using the Behaviour Change Wheel. Research in Social and Administrative Pharmacy, 2020, 16, 1746-1753.	3.0	18
21	A Continuing Professional Development Program for Pharmacists Implementing Pharmacogenomics into Practice. Pharmacy (Basel, Switzerland), 2020, 8, 55.	1.6	26
22	Exploring pharmacy service users' support for and willingness to use community pharmacist prescribing services. Research in Social and Administrative Pharmacy, 2019, 15, 575-583.	3.0	14
23	Lessons learned from 3 attempts to use data sources to evaluate pharmacist prescribing in Ontario. Canadian Pharmacists Journal, 2019, 152, 234-240.	0.8	O
24	Sex Differences in the Prevalent Use of Oral Formulations of Cholinesterase Inhibitors in Older Adults with Dementia. Drugs and Aging, 2019, 36, 875-884.	2.7	5
25	Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A populationâ€based study of older women and men with diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 2394-2404.	4.4	102
26	Management of Sleep Disorders in Communityâ€Dwelling Older Women and Men at the Time of Diagnosis. Journal of the American Geriatrics Society, 2019, 67, 2094-2101.	2.6	9
27	Assessing the Scope and Appropriateness of Prescribing Cascades. Journal of the American Geriatrics Society, 2019, 67, 1023-1026.	2.6	48
28	Deprescribing: Future directions for research. Research in Social and Administrative Pharmacy, 2019, 15, 801-805.	3.0	54
29	Pharmacy in the 21st century: Enhancing the impact of the profession of pharmacy on people's lives in the context of health care trends, evidence and policies. Canadian Pharmacists Journal, 2019, 152, 45-53.	0.8	39
30	Deprescribing recommendations: An essential consideration for clinical guideline developers. Research in Social and Administrative Pharmacy, 2019, 15, 806-810.	3.0	21
31	Integrating medication samples into the traditional community pharmacy supply chain: a feasibility study. International Journal of Pharmacy Practice, 2018, 26, 284-287.	0.6	O
32	Interprovincial Variation of Psychotropic Prescriptions Dispensed to Older Canadian Adults. Canadian Geriatrics Journal, 2018, 21, 269-273.	1.2	13
33	Initial Cholinesterase Inhibitor Therapy Dose and Serious Events in Older Women and Men. Journal of the American Geriatrics Society, 2018, 66, 1692-1699.	2.6	11
34	Comparison of prescribing practices for older adults treated by female versus male physicians: A retrospective cohort study. PLoS ONE, 2018, 13, e0205524.	2.5	20
35	Prioritizing intraprofessional collaboration for optimal patient care: A call to action. Canadian Pharmacists Journal, 2018, 151, 170-175.	0.8	9
36	Identifying frailty in primary care: a qualitative description of family physicians' gestalt impressions of their older adult patients. BMC Family Practice, 2018, 19, 61.	2.9	17

#	Article	IF	Citations
37	Exploring deprescribing opportunities for community pharmacists: Protocol for a qualitative study. Canadian Pharmacists Journal, 2018, 151, 228-232.	0.8	4
38	Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Canadian Family Physician, 2018, 64, 17-27.	0.4	94
39	Pharmacist prescribing: A scoping review about the views and experiences of patients and the public. Research in Social and Administrative Pharmacy, 2017, 13, 1-16.	3.0	43
40	Lack of Evidence to Guide Deprescribing of Antihyperglycemics: A Systematic Review. Diabetes Therapy, 2017, 8, 23-31.	2.5	30
41	Beyond Plan B: A Qualitative Study of Canadian Pharmacists' Emergency Contraception Counselling Practices. Journal of Obstetrics and Gynaecology Canada, 2017, 39, 1021-1027.	0.7	10
42	Incorporating sex, gender and vulnerable populations in a large multisite health research programme: The Ontario Pharmacy Evidence Network as a case study. Health Research Policy and Systems, 2017, 15, 20.	2.8	4
43	Sex and gender-based analysis in pharmacy practice research: A scoping review. Research in Social and Administrative Pharmacy, 2017, 13, 1045-1054.	3.0	11
44	Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline. Canadian Family Physician, 2017, 63, 832-843.	0.4	72
45	Medication reconciliation interventions in ambulatory care: A scoping review. American Journal of Health-System Pharmacy, 2016, 73, 1845-1857.	1.0	19
46	Effect of a Proton Pump Inhibitor Deprescribing Guideline on Drug Usage and Costs in Long-Term Care. Journal of the American Medical Directors Association, 2016, 17, 673.e1-673.e4.	2.5	42
47	Canadian "minor ailments―programs. Canadian Pharmacists Journal, 2015, 148, 302-304.	0.8	12
48	Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: protocol for a multiple case study. Implementation Science, 2015, 10, 91.	6.9	22
49	MedIntegrate. Canadian Pharmacists Journal, 2014, 147, 300-306.	0.8	4
50	Caseâ€crossover study design in pharmacoepidemiology: systematic review and recommendations. Pharmacoepidemiology and Drug Safety, 2013, 22, 1146-1153.	1.9	47
51	Group Interprofessional Chronic Pain Management in the Primary Care Setting: A Pilot Study of Feasibility and Effectiveness in a Family Health Team in Ontario. Pain Research and Management, 2013, 18, 237-242.	1.8	7
52	Intimate partner violence: patients' experiences and perceptions in family practice. Family Practice, 2012, 29, 593-600.	1.9	24
53	Monitoring physical functioning as the sixth vital sign: evaluating patient and practice engagement in chronic illness care in a primary care setting—a quasi-experimental design. BMC Family Practice, 2012, 13, 29.	2.9	33
54	An Evaluation of Teaching Physical Examination to Pharmacists. Canadian Pharmacists Journal, 2012, 145, 174-179.e1.	0.8	22

#	Article	lF	CITATIONS
55	The effect of pharmacist education on asthma treatment plans for simulated patients. International Journal of Clinical Pharmacy, 2007, 29, 228-239.	1.4	33